Clinical Trial: Phase III Trial to Investigate Efficacy and Safety of Vilobelimab in Ulcerative Pyoderma Gangrenosum
Study Status: RECRUITING
Recruit Status: RECRUITING
Study Type: INTERVENTIONAL
Official Title: A Randomized, Double-blind, Placebo-controlled, Multicenter, Adaptive Phase III Trial to Investigate Efficacy and Safety of Vilobelimab in the Treatment of Ulcerative Pyoderma Gangrenosum
Brief Summary: A randomized, double-blind, placebo-controlled, multicenter, adaptive phase III trial to investigate efficacy and safety of vilobelimab in the treatment of ulcerative pyoderma gangrenosum
Detailed Summary:
Sponsor: InflaRx GmbH
Current Primary Outcome: Efficacy of Vilobelimab compared to placebo - complete closure of the ulcer
Original Primary Outcome: Efficacy of Vilobelimab compared to placebo - complete closure of the ulcer
Current Secondary Outcome:
Original Secondary Outcome:
Information By: InflaRx GmbH
Dates:
Date Received: June 29, 2023
Date Started: August 15, 2023
Date Completion: August 15, 2023
Last Updated: November 11, 2023
Last Verified: November 01, 2023